A Comparative Assessment of Systematic Literature Review Requirements for Health Technology Assessment, Globally

Author(s)

Wright C1, Swanston A1, Nicholson L2, Marjenberg Z1
1Maverex Ltd, Newcastle upon Tyne, Tyne and Wear, UK, 2Maverex Ltd, Manchester, CHW, UK

OBJECTIVES: An integral part of a health technology assessment (HTA) is a systematic literature review (SLR); an unbiased, high-quality synthesis of available evidence. For many HTA agencies, guidance on data sources, methodology, required outcomes, and reporting of the SLR varies considerably. The objective of this study was to conduct a comparative assessment of the clinical and economic SLR methodological requirements of HTA agencies in different countries around the world.

METHODS: We searched eight HTA agency websites (www.pbs.gov.au [Australia], www.cadth.ca, [Canada], www.nice.org.uk [England], www.has-sante.fr [France], www.g-ba.de [Germany], www.zorginstituutnederland.nl [Netherlands], www.ace-hta.gov.sg [Singapore], www.tlv.se [Sweden]) to identify guidance on the use of SLRs in HTA. Relevant information was extracted and compared.

RESULTS: All eight countries require an SLR of clinical data for the technology and its comparators. A quality assessment of included studies and critical appraisal of randomized and non-randomized clinical trials is also requested. Only three countries (Australia, England, and France) requested an SLR of economic models for the technology, with the latter two also requiring a critical appraisal of the models. SLRs of utility, resource use, and cost data were less frequently mandated, with only NICE in England suggesting the inclusion of an SLR of utility data. The most stringent requirements were found in England and France.

CONCLUSIONS: While all eight countries require an SLR as part of the HTA submission, a limited consensus was found in terms of SLR requirements. The specific requirements for conducting SLRs in HTAs vary globally due to differences in regulatory frameworks, healthcare systems, and decision-making processes. Differences between HTA agency guidance is a consideration when carrying out an SLR for use in HTA submissions in global markets. Efficiencies in conducting SLRs that can fulfil the requirements for several HTA bodies can be made with strategic planning.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)

Code

HTA360

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×